Brief: FDA Accepts Hookipa's Investigational New Drug Application For HB-300 For Treatment Of Metastatic Castration-Resistant Prostate Cancer
25/07/2022 14:07
July 25 (Reuters) - HOOKIPA Pharma Inc HOOK.O :
* FDA ACCEPTS HOOKIPA’S INVESTIGATIONAL NEW DRUG APPLICATION FOR HB-300
FOR THE
TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
* HOOKIPA PHARMA INC - NOVEL ARENAVIRAL IMMUNOTHERAPY IS DIRECTED AGAINST
PROSTATE
CANCER TARGETS PAP AND PSA; PHASE 1/2 TRIAL TO COMMENCE BY EARLY 2023
Source text for Eikon: ID:nGNX9Grsn9
Further company coverage: HOOK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hookipa Pharma
See all newsBrief: Hookipa Pharma Announces Sale Of Oncology Assets To Neotrail Therapeutics
Brief: Hookipa Pharma Announces Intention To Voluntarily Delist And Deregister Its Common Stock
Hookipa Pharma Inc Expected To Post A Loss Of $1.04 A Share: Earnings Preview
Brief: Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)